SPAC Merger Disclosure After the Litigation Wave: What the Courts Settled About Projections

De-SPAC transactions — mergers between a special purpose acquisition company and a private target — generated one of the heaviest securities-litigation waves of the early 2020s, and by 2026 the resulting case law has largely settled two questions: target-company projections needed meaningful qualifications to be not misleading, and claims that sponsors structurally overpaid have mostly failed. The Delaware Court of Chancery's 2025 post-trial rulings, including its refusal to impose liability for using a 15 percent discount rate in pipe-influenced valuations, marked the practical end of the fiduciary-theory attack on the structure itself.

USA Post publishes information about corporate litigation, not legal advice or investment advice.

What was the wave of SPAC litigation about?

Between 2021 and 2023, plaintiffs filed two parallel tracks of suits. Securities class actions in federal court alleged registration statements for de-SPAC mergers concealed problems at targets — accounting irregularities, collapsing demand — citing the non-exclusive private right of action under the Securities Act. Derivative suits in Delaware advanced a structural theory: because sponsors' promote paid off only if a deal closed, sponsors allegedly had an incentive to overpay and foist an unfair merger on public shareholders. The Delaware docket consolidated into In re MultiPlan Corp. Stockholders Litigation, the lead test of both theories.

What did the MultiPlan line actually decide?

In 2023, the Delaware Court of Chancery sustained the core of the structural claim, holding that MultiPlan's shareholders were akin to limited partners and that the complaint supported an inference the merger was driven by the sponsors' and target's interests, not the public stockholders'. That ruling, allowed to stand by the Delaware Supreme Court in March 2025, established that conflicted de-SPAC mergers will be reviewed for entire fairness rather than under the cleansing safe harbor of Section 102(b)(7) and the private-ordering framework of Corwin. But liability was never the end of the story: on remand-related proceedings and parallel post-trial decisions in 2025, the court repeatedly found that fair process problems did not prove that the price was unfair — declining to second-guess 15-to-20 percent discount rates or sponsor-driven timing where market evidence supported value.

What did courts say about projections?

Three recurring disclosure holdings emerged. First, a projection is misleading if presented as management's own while the deal team knows management does not stand behind it — the disclosure doctrine developed in projection cases since 2021 applied squarely to de-SPAC target models. Second, non-GAAP and adjusted figures need reconciliation-grade care even in a proxy: the Southern District of New York's rulings on multi-year growth stories held that undisclosed internal skepticism made optimistic curves actionable. Third, line-item disclosure of a banker's analysis does not cure the omission of the banker's known conflicts; sponsors who retained bankers paid in promote economics faced viable claims on that basis. The practical synthesis: projections must be published with their assumptions, their authors' belief in them, and their alternatives — the "line-item" doctrine is a floor, not a shield.

What happened to the PIPE-conflict theory?

Mostly rejected. Plaintiffs argued PIPE investors negotiated collateral benefits that made them promoters with duties to public shareholders. Courts in Delaware and New York consistently declined to graft fiduciary status onto ordinary-anchor investors, holding that buying stock in a registered transaction, however large, does not make a buyer a controlling stockholder absent actual control over the merger's terms. The theory survives only where a PIPE investor obtained veto rights or side economics tied to closing — facts rarely pleaded plausibly after 2023 amendments to complaint practice.

What should boards of surviving SPACs take from the settlements?

1. Deal projections require a documented, contemporaneous belief by their authors — the responsible corporate officer must actually adopt them.
2. Disclose known internal disagreement with projections or omit the projections; the middle path is where liability lived.
3. Assume entire fairness review where the sponsor's economics dominate; structure independent protection — a truly independent special committee with genuine bargaining power — before announcing terms.
4. Banker conflicts, including fees contingent on closing, belong in the proxy's narrative, not a footnote.
5. Treat Section 102(b)(7) exculpation as unavailable for loyalty claims arising from promote-driven processes.

Is the SPAC litigation era over?

As a wave, largely yes: new de-SPAC filings slowed to a trickle after 2022, and the 2025 rulings removed both the plaintiffs' best structural theory, by rejecting liability at trial, and sponsors' chief structural defense, by rejecting cleansing. What remains is ordinary-course enforcement — SEC actions against de-SPAC disclosure and accounting under the framework settled since 2022 — and a template for the next novel structure: whenever a deal's economics reward insiders only on closing, courts will review the process with the entire-fairness microscope this litigation wave sharpened.